Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
12.04
+0.03 (0.25%)
At close: Feb 20, 2026, 4:00 PM EST
12.19
+0.15 (1.25%)
After-hours: Feb 20, 2026, 7:48 PM EST
Omeros Employees
Omeros had 202 employees as of December 31, 2024. The number of employees increased by 4 or 2.02% compared to the previous year.
Employees
202
Change (1Y)
4
Growth (1Y)
2.02%
Revenue / Employee
n/a
Profits / Employee
-$599,797
Market Cap
853.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 202 | 4 | 2.02% |
| Dec 31, 2023 | 198 | 2 | 1.02% |
| Dec 31, 2022 | 196 | -17 | -7.98% |
| Dec 31, 2021 | 213 | -64 | -23.10% |
| Dec 31, 2020 | 277 | 19 | 7.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 596 |
| Phathom Pharmaceuticals | 427 |
| KalVista Pharmaceuticals | 270 |
| Xencor | 250 |
| ARS Pharmaceuticals | 167 |
| Cullinan Therapeutics | 111 |
| Arbutus Biopharma | 44 |
| Bright Minds Biosciences | 26 |
OMER News
- 4 days ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 25 days ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 6 weeks ago - Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript - Seeking Alpha
- 6 weeks ago - Omeros prices transplant complication drug at $36,000 per dose - Reuters
- 2 months ago - Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Business Wire
- 2 months ago - Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely - Seeking Alpha
- 2 months ago - Gold Edges Lower; Omeros Shares Jump - Benzinga
- 2 months ago - US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters